menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Postmenopausal Osteoporosis: Managing Patients at High Risk for Fracture

Postmenopausal Osteoporosis: Managing Patients at High Risk for Fracture
RestartResume

We don’t ignore the symptoms of a heart attack, so why do we often ignore fragility fractures as a sign of postmenopausal osteoporosis? 

  • Sponsored by

  • Overview

    Just as a heart attack is an urgent indicator of heart disease, a fragility fracture in a postmenopausal woman signals that she may have underlying postmenopausal osteoporosis, and there should be urgency to treat the disease. Joining us to share some historical perspectives on postmenopausal osteoporosis and information about TYMLOS (abaloparatide), a treatment option for those patients with postmenopausal osteoporosis at high risk for fracture, is Dr. David Dempster.

  • IMPORTANT SAFETY INFORMATION

    INDICATION AND IMPORTANT SAFETY INFORMATION

    TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.

    Limitations of Use 
    Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.

    IMPORTANT SAFETY INFORMATION 
    WARNING: RISK OF OSTEOSARCOMA

    • Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80 mcg dose. It is unknown if TYMLOS will cause osteosarcoma in humans.
    • The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton.
    • Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.

    Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

    Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

    Hypercalciuria and Urolithiasis:TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

    Adverse Reactions: The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.

    Please see Important Safety Information  and Full Prescribing Information, including Boxed Warning, at TYMLOShcp.com.

    References

    1. Abbasi J. Amid osteoporosis treatment crisis, experts suggest addressing patients’ bisphosphonate concerns. JAMA. 2018 Jun 26; 319: 2464–2466.
    2. Ball P. Life’s lessons in design. Nature. 2001; 409(6818): 413–416.
    3. Bauer W, et al. Studies of calcium and phosphorus metabolism. J Exp Med. 1929 Jan 1; 49(1): 145–162.
    4. Bijlsma AY, et al. Chronology of age-related disease definitions: osteoporosis and sarcopenia. Ageing Res Rev. 2012 Apr; 11(2): 320–324.
    5. Binkley N, et al. Osteoporosis in crisis: it's time to focus on fracture. J Bone Miner Res. 2017 Jul; 32(7): 1391–1394.
    6. Bone HG, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018 Aug; 103(8): 2949–2957.
    7. Camacho PM, et al. American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016. Endocr Pract. 2016 Sep 2; 22(suppl 4): 1–42.
    8. ClinicalTrials.gov. NCT00542425, NCT01343004. Accessed January 29, 2019.
    9. Cosman F, et al. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017 Feb; 32: 198–202.
    10. Delmas PD, et al. Underdiagnosis of vertebral fractures is a worldwide problem: the impact study. J Bone Miner Res. 2005 Apr; 20: 557–563.
    11. Gehlbach S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res. 2012 Mar; 27: 645–653.
    12. Gillespie CW, Morin PE. Osteoporosis-related health services utilization following first hip fracture among a cohort of privately-insured women in the united states, 2008-2014: an observational study. J Bone Miner Res. 2017 May; 32: 1052–1061.
    13. Greenspan SL, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012 Mar; 60: 455–61.
    14. Gupta MJ, et al. Rush fracture liaison service for capturing "missed opportunities" to treat osteoporosis in patients with fragility fractures. Osteoporosis Int. 2018 Aug; 29: 1861–1874.
    15. Hattersley G, et al. Binding selectivity of abaloparatide for pth-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016 Jan; 157: 141–149
    16. Khosla S, Shane EJ. A crisis in the treatment of osteoporosis. J Bone Miner Res. 2016 Aug; 31: 1485–1487.
    17. Khosla S, et al. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2017 Mar; 32: 424–430.
    18. Lewiecki EM, et al. American Association of Nurse Practitioners 2018 National Conference. June 26–29, 2018; Denver,CO.
    19. Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015 Jun; 277: 650–661.
    20. Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015 Jun; 277: 650–661.
    21. Martin TJ. Parathyroid hormone-related protein, its regulation of cartilage and bone development, and role in treating bone diseases. Physiol Rev. 2016 Jul; 96: 831–871.
    22. Miller PD, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016 Aug; 316: 722–733.
    23. National Committee for Quality Assurance. https://www.ncqa.org/report-cards/health-plans/state- of-health-care-quality-report/. Accessed September 28, 2018.
    24. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001; 285: 785–795.
    25. Parkinson IH, Fazzalari NL. Characterisation of trabecular bone structure. Stud Mechanobiol Tissue Eng Biomater. 2013; 5: 31–51.
    26. Patlak M. Bone builders: the discoveries behind preventing and treating osteoporosis. FASEB Journal. 2001 Aug; 15: 1677e–1677e.
    27. Potts JT. Parathyroid hormone: past and present. J Endocrinol. 2005 Dec; 187(3): 311–325.
    28. Radius. TYMLOS. Data on file.
    29. Santora L, Skolbekken JA. From brittle bones to standard deviations: the historical development of osteoporosis in the late twentieth century. Science, Technology, & Human Values. 2011; 36: 497–521.
    30. Schatz, Weber. Adverse drug reactions. CNS/Pharmacy Practice. 2015.
    31. Seeman E, Martin TJ. Co-administration of antiresorptive and anabolic agents: a missed opportunity. J Bone Miner Res. 2015 May; 30: 753–764.
    32. Siris ES, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004 May; 164(10): 1108–1112.
    33. Solomon DH, et al. Osteoporosis medication use after hip fracture in u.s. patients between 2002 and 2011. J Bone Miner Res. 2014 Sep; 29: 1929–1937.
    34. TYMLOS [package insert]. Waltham, MA: Radius Health, Inc; 2018.
    35. van Geel TA, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009 Jan; 68: 99–102.
    36. Wainwright SA, et al. Hip fracture in women without osteoporosis. J Clinical Endocrinol & Metab. 2005 May; 90(5): 2787–2793

    TYMLOS is a registered trademark of Radius Health, Inc.
    © 2020 Radius Health, Inc. All rights reserved.
    06/20. TYM-US-03614

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/23/20